HR Generalist

UNIQURE N.V. QURE INVESTORS: contact Kirby McInerney LLP about the firm's securities investigation following 37.3% share drop. NEW YORK-(BUSINESS WIRE)-The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. What Happened? On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Company's lead pipeline candidate to treat Huntington's disease. The 48-month data revealed a smaller treatment benefit than the one the Company reported at 36 months. Specifically, AMT-130 showed a "44% slowing of disease progression" at 48 months under the composite Uniform Huntington's Disease Rating Scale, compared to a 75% disease slowing at 36 months. In June, uniQure had announced that the Company intended to submit an application to the FDA to bring AMT-130 to the market and did so on September 2, 2026, submitting a Biologics License Application to the FDA based upon its 36-month data analysis. On the disclosure of the Company's 48-month AMT-130 results, the price of uniQure shares declined by $14.60 per share, or approximately 37.3%, from $39.11 per share on September 28, 2026 to close at $24.51 on September 29, 2026. What Should I Do? At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired uniQure securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP's website. More News From Kirby McInerney LLP NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On June 2, 2026, the FDA published a warning letter that detailed Medline's "significant violations of Curr... NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Alphabet Inc. ("Alphabet" or the "Company") (NASDAQ: GOOGL; GOOG) securities between May 19, 2026 and July 16, 2026, inclusive ("the Class Period"). If you suffered a loss on your Alphabet investments, you have until December 1, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged to fill ou... NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Coastal Financial Corporation ("Coastal" or the "Company") (NASDAQ: CCB) securities between October 28, 2024 and July 29, 2026, inclusive ("the Class Period"). If you suffered a loss on your Coastal investments, you have until December 1, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged... Kirby McInerney LLP. NASDAQ:QURE Release Versions

Bragar Eagel & Squire, P.C. is investigating Medline Inc. on behalf of Medline stockholders and Encourages Investors to contact the firm. Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medline (MDLN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Medline and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648. NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) - What's Happening: * Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN) on behalf of Medline stockholders. Our investigation concerns whether Medline has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: * On June 2, 2026, the FDA published a warning letter that detailed Medline's "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals," including failing "to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." On this news, the price of Medline shares declined by $2.56 per share, or approximately 7.2%, from $35.75 per share on to June 1, 2026 to close at $33.19 on June 2, 2026. * On August 5, 2026, Medline released its second quarter 2026 financial results and revealed during its earnings call that some of the remediation steps it has taken in response to the FDA's letter, such as taking products off the market, have "result[ed] in earnings loss." On this news, the price of Medline shares declined by $5.37 per share, or approximately 12.8%, from $42.04 per share on August 4, 2026 to close at $36.67 on August 5, 2026. Next Steps: * If you purchased or otherwise acquired Medline shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 [email protected] www.bespc.com

James River Home Health selects Medline vendor. Medline announced it signed a new Prime Vendor agreement with James River Home Health & Hospice, a home health and hospice provider serving patients and families across its care network, a James River Home Health Medline Prime Vendor arrangement aimed at supporting the provider's growth. What the James River Home Health Medline Prime Vendor agreement includes. Through the agreement, James River gains access to Medline's medical-surgical product portfolio and distribution capabilities, intended to streamline ordering and timely, reliable delivery of supplies. The Prime Vendor model typically consolidates a provider's purchasing with one distributor, which can simplify logistics and standardize the products clinicians use. Clinical tools added to the arrangement. James River will also implement Medline's Skin Health Program and use the NE1 Wound Tool, which helps clinical staff assess and document wounds. Pairing supply purchasing with clinical programs suggests the agreement is meant to support care consistency as well as procurement. James River's rationale for the James River Home Health Medline Prime Vendor deal. David Gilligan, CFO of James River Home Health & Hospice, described the organization as a growing provider focused on expanding access to high-quality care. He said building infrastructure and partnerships to support clinicians and maintain consistency is a priority, and that Medline's scale, expertise, and post-acute focus make it a strong partner as James River serves more patients. Why consistency matters as providers grow. Expanding home-based providers often add clinicians and locations quickly, which can produce variation in the supplies and documentation practices staff use. Standardizing on a single vendor and shared tools is one way to keep practices uniform across a growing network. Medline's perspective on the James River Home Health Medline Prime Vendor agreement. Renee Fisher, senior vice president of national field sales for post-acute care at Medline, said the company is proud to work with James River as it expands access to home-based care. She said the combination of reliable product access and post-acute supply chain solutions is meant to let James River's teams stay focused on patients and families. About Medline. Medline describes itself as the largest provider of medical-surgical products and supply chain solutions serving all points of care, employing more than 45,000 people worldwide and operating in more than 100 countries. The company trades on Nasdaq under MDLN and is headquartered in Northfield, Ill. How the James River Home Health Medline Prime Vendor agreement fits home-based care trends. The announcement reflects a theme raised at recent home-based care events, where operators said growth must rest on operational infrastructure and discipline. Supply chain reliability, clinical documentation, and compliance are part of that backbone, particularly as federal fraud enforcement and documentation scrutiny continue to affect home health and hospice providers. Why Wound documentation is a notable detail. Wound assessment and documentation are areas where consistent records matter for both clinical care and payer or regulatory review. Providing a standard tool for staff may help James River document care uniformly, though the announcement did not describe outcomes or metrics. What the James River Home Health Medline Prime Vendor agreement means going forward. The agreement gives James River a single supply and clinical program partner as it grows, and it gives Medline another post-acute customer. Because financial terms, contract length, and the size of James River's network were not disclosed, the practical impact on costs and operations cannot be assessed from the announcement alone. What to watch going forward. Observers will likely watch whether James River reports operational or clinical results from the Skin Health Program and NE1 Wound Tool, and whether more home health and hospice providers pursue similar prime vendor and clinical program bundles. As a company announcement, the James River Home Health Medline Prime Vendor news is best read as a signal of provider growth and vendor consolidation in post-acute care rather than as evidence of measured performance gains.